Are the tumour suppressive mechanisms that mitigate the oncogenic effects of excessive ERK1/2 activity still at least partially functional in some tumour cells but not others, and does BRAFV600Evs. KRASG13D influence this? This evidence concerns the gene MAPK3 and neoplasm.